VCYT / What Makes Veracyte (VCYT) a New Buy Stock

Veracyte (VCYT) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0. more_horizontal

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quar more_horizontal

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relati more_horizontal

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quart more_horizontal

Veracyte's revenue grew at a healthy clip in the fourth quarter. The genomic test company's financial health looks solid. more_horizontal

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Ch more_horizontal

Start Time: 16:30 January 1, 0000 5:29 PM ET Veracyte, Inc. (NASDAQ:VCYT ) Q4 2022 Earnings Conference Call February 22, 2023, 16:30 PM ET Company Par more_horizontal

Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the quarter ended December 2022. Do the numbers hold c more_horizontal